Please login to the form below

Not currently logged in
Email:
Password:

Cannabinoids

This page shows the latest Cannabinoids news and features for those working in and with pharma, biotech and healthcare.

Latest news

  • GW Pharma's cannabis-based medicine to be tested in dementia GW Pharma's cannabis-based medicine to be tested in dementia

    dementia. Sativex, which is approved to treat MS, is a peppermint-flavoured mouth spray that contains a 1:1 ratio of two key cannabinoids found in the cannabis plant.

  • The Final Frontier The Final Frontier

    Maybe. The Canadian Pain Society recently moved cannabinoid therapy up from a fourth-line treatment option to a third-line treatment option for neuropathic pain.

  • US approval for first ever cannabis-based medicine US approval for first ever cannabis-based medicine

    Having battled against misconceptions about the therapeutic mechanism of their cannabinoid medicines, and having persuaded regulators in the UK, US and beyond to accommodate their medicines, the Epidiolex approval is the ... These patients deserve and

  • The year of the blockbuster The year of the blockbuster

    Epidiolex from GW Pharmaceuticals:With a PDUFA date in June, GW Pharmaceuticals’ Epidiolex (plant-derived cannabidiol) has the potential to become the first cannabinoid-based anti-epileptic medication.

  • J&J partner drive nets 15 new deals, and another NASH drug J&J partner drive nets 15 new deals, and another NASH drug

    The latest crop of 15 new deals has just been revealed and includes a collaboration and option agreement with Bird Rock Bio, which has a cannabinoid receptor 1 (CB1) targeting antibody

More from news
Approximately 1 fully matching, plus 34 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    3. Epidiolex – leading the flowering therapeutic cannabinoid market. The last 12 months have seen a huge growth in interest in the therapeutic potential of cannabis, with authorities now allowing regulated access

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • GW Pharmaceuticals strengthens research and development team GW Pharmaceuticals strengthens research and development team

    AstraZeneca. He said: “I am truly excited about the opportunity to continue the work of providing regulatory approved cannabinoid-based pharmaceutical medicines to patient’s with high unmet medical needs and ... He said: “Having now worked for the

  • GW hires Pfizer’s Kenneth Sommerville GW hires Pfizer’s Kenneth Sommerville

    Appointed VP clinical research at company specialising in cannabinoids. Dr Kenneth Sommerville has left his role at pharma giant Pfizer to join GW Pharma. ... GW's research is focused on the development of cannabinoids. This includes Sativex, which

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • "Legal highs" ruling leaves illegal labs laughing

    The synthetic cannabinoid Spice can cause seizures, paranoid delusions and psychosis, and the Centre for Social Justice recorded 97 deaths from legal highs in the UK in 2012.  . ... There are also many agents that have crossed the line from illegal to

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Graphite Digital

Graphite is a digital agency which partners with globally respected healthcare organisations to create powerful digital experiences....

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics